Philippe Dro joined GlycoVaxyn as Chief Executive Officer and member of the Supervisory Board in May 2008. He has 20 years entrepreneurial experience in the life science industry, including pharma, biotech and medtech companies.
Most recently, he was Chairman and CEO of Endoart SA, a medtech company developing telemetric driven implants for cardiac disease and obesity, that was sold to Allergan, Inc. From 1999 to 2003, Dr Dro was Chief Operating Officer (COO) and part of the founding team of AXOVAN AG, a GPCR focused drug discovery company, that grew the company to a clinical-stage entity which was acquired by Actelion Ltd. Prior to this, he held the position of COO and director of the Board of Antares Pharma, Inc (AMEX: AIS), a drug delivery company formed by the merger of Permatec Group and Mediject, Inc. He also held executive director positions at Skyepharma Ltd during its listing on the LSE and in finance at Sandoz Pharma AG (now Novartis).
Dr Dro earned a Pharm D from University of Grenoble (France) and an MBA jointly from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
Michael Wacker co-founded GlycoVaxyn in 2004 and is now responsible for its technology and product development, as well as development collaborations.
He invented GlycoVaxyn's technology with Professor Markus Aebi at the Institute of Microbiology of the Swiss Federal Institute of Technology (ETH) during his PhD and post-doctoral research. He is the author of several publications in international scientific journals, including Science and PNAS. He graduated in biochemistry from the ETH in Zurich.
